Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-driven CARCIK-CD19 strategy in relapsed/refractory BCP-ALL
2024-519394-19-00Phase 2Completed
- Sponsor
- Fondazione Matilde Tettamanti
- Start
- Dec 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CARCIK-CD19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Fondazione Matilde Tettamanti. Primary endpoints: Overall response rate at 28 days after first CARCIK-CD19 administration and Duration of response from day 70 in responders. Started Dec 2024; status: completed.
02
Drugs
CARCIK-CD19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2024-519394-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519394-19-00.